
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Pharmaceutical Technology Europe
The EU is trying to bring some clearer definition to the borders of its pharmaceutical legislation...
over 21 years ago
Nanotechnology Applications for Drug Deliveryover 21 years ago
Nanotech Not Big Enough for Pharma?over 21 years ago
Protecting Intellectual Property Prior to Commercializationover 21 years ago
Ion Exchange Resinates — The Technology Behind the Mysteryover 21 years ago
Maintaining the Safety of EU Drugs





